- Effective August 1, 2025, the agreement covers the United States, Canada, Mexico, Central America, and the Caribbean.
- The Bormed™ portfolio includes specialized polyethylene and polypropylene grades for medical use.
- IMCD has been Borealis' Bormed distributor in Europe since 2021.
- The partnership aims to meet healthcare industry's demand for reliable supply and regulatory compliance.
Agreement Overview
Effective August 1, 2025, Borealis has appointed IMCD as the official distribution partner for its Bormed™ portfolio in the Americas. This agreement covers the United States, Canada, Mexico, Central America, and the Caribbean, significantly enhancing access to Borealis’ healthcare polyolefins in these regions.
Bormed™ Portfolio
The Bormed™ portfolio consists of specialized polyethylene and polypropylene grades designed for medical devices, pharmaceutical packaging, and diagnostic applications. These materials are suitable for various processing technologies, including injection molding, and are built on the principles of service, commitment, and conformance.
Partnership Background
IMCD, with its extensive knowledge of polyolefins for healthcare applications, has been Borealis’ Bormed distributor in most European markets since 2021. The new agreement extends this successful partnership model to the Americas, aiming to meet the healthcare industry's demand for reliable supply and regulatory compliance.
Strategic Goals
The collaboration between Borealis and IMCD is a strategic move to strengthen their presence in the Americas and ensure that the Bormed™ portfolio is represented by a partner with the expertise and reach to serve this critical market. The partnership focuses on providing high-quality materials, technical guidance, and reliable local service to meet the strict regulatory and performance demands of the healthcare sector.
